Summary:
- Novartis, a leading pharmaceutical company, has reported solid sales and core operating income growth in the third quarter of the year.
- The company has made significant progress in its pipeline, with several new drug candidates advancing through clinical trials.
- Novartis has reaffirmed its financial guidance for the full year 2025, indicating a strong outlook for the company's future performance.